Resolution of hyphaema following intracameral injection of tenecteplase in a Stock Horse.
Intracameral injection of tissue plasminogen activator has been suggested as a means of hastening the clearance of blood from the anterior chamber and reducing the risk of synechia and fibrotic membrane formation in horses with hyphaema. The following report describes a case of ocular trauma in which intracameral injection of tenecteplase (TNK), a new-generation plasminogen activator, resulted in rapid resolution of hyphaema and successful outcome. However, a large dose (1 mg) was administered and may have been associated with retinopathy and keratopathy. TNK may be an effective treatment for equine hyphaema and further controlled clinical or experimental studies are required to determine its efficacy and safety profiles.
School of Animal and Veterinary Sciences, Charles Sturt University, Wagga Wagga, New South Wales, Australia. daverendle@me.com
D I
DI
Rendle
K J
KJ
Hughes
D000818:Animals; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D016489:Head Injuries, Closed / Q000150:complications / Q000662:veterinary; D006734:Horse Diseases / Q000188:drug therapy* / Q000209:etiology; D006736:Horses; D006988:Hyphema / Q000188:drug therapy / Q000209:etiology / Q000662:veterinary*; D008297:Male; D000077785:Tenecteplase; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D016896:Treatment Outcome
D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator; D000077785:Tenecteplase